Search the Newsreel

Takeda wins U.S. FDA approval for narcolepsy drug ORZEYFUL

Takeda Pharmaceutical has received U.S. FDA approval for ORZEYFUL (oveporexton) to treat adults with narcolepsy type 1, making it the first approved orexin agonist for the disorder. The approval, granted on August 5, 2026, is based on positive Phase 3 trial results showing significant …

Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful

Takeda has received FDA approval for Orzeyful (oveporexton), a first-in-class, twice-daily tablet for adults with narcolepsy type 1 (NT1). This treatment addresses the root cause of the condition by mimicking the body's orexin cycle. Takeda anticipates peak sales for Orzeyful to be between $2 …

Take-Two Interactive Software Target of Unusually Large Options Trading (NASDAQ:TTWO)

Take-Two Interactive Software (NASDAQ:TTWO) experienced an unusually large surge in options trading, with call option activity increasing by 413% compared to its average volume. Despite a slight dip in stock price, analysts maintain a "Buy" rating with an average price target of $294.44, though …

Takeda’s Orzeyful approved in US as first-in-class orexin treatment for narcolepsy Type 1

The FDA has approved Takeda's Orzeyful (oveporexton) as the first medication to directly address the loss of orexin signaling in Narcolepsy Type 1. Unlike previous treatments that only offered symptomatic relief, Orzeyful targets the underlying cause by activating the brain's orexin receptor 2 (OX2R). …

Takeda Wins FDA Nod For ORZEYFUL, First Orexin Therapy For Narcolepsy Type 1

(RTTNews) - Takeda (TAK) announced that the U.S. FDA has approved ORZEYFUL, an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1) in adults. Narcolepsy type 1 is a rare, chronic neurological disorder caused by orexin deficiency, affecting an …

Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict

Takeda Pharmaceuticals is arguing that an $885 million antitrust verdict against it, related to delaying generic competition for its IBS drug Amitiza, should be reduced. The drugmaker contends that rebates it paid and Medicare subsidies received by health plans should be factored into the …

US FDA approves Takeda's sleep disorder pill

The U.S. Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals' oral drug, Orzeyful, for narcolepsy, making it the first treatment to target all symptoms of the rare sleep disorder. Orzeyful works by directly addressing the loss of orexin signaling, which is the cause …

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda announced that the U.S. FDA has approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for treating narcolepsy type 1 (NT1) in adults. This first-in-class medicine targets the underlying orexin deficiency, offering holistic treatment beyond symptom relief. The availability of ORZEYFUL is …

Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments

The FDA has approved Takeda's narcolepsy drug, Orzeyful, a twice-daily pill that is an orexin receptor agonist. This approval is significant as it marks a new class of treatment for narcolepsy type 1, offering an alternative to existing therapies which have risks of misuse …

Take-Two Set to Report Q1 Earnings: What's in the Cards for the Stock?

Take-Two Interactive Software TTWO is scheduled to report its first-quarter fiscal 2027 results on Aug. 7, 2026. For the first quarter of fiscal 2027, Take-Two expects GAAP net revenues between $1.45 billion and $1.50 billion. The company projects a loss per share of 23 …

Take-Two Interactive Software Insiders Sold US$42m Of Shares Suggesting Hesitancy

Take-Two Interactive Software insiders recently sold US$42 million worth of shares, despite the company's strong performance, with the stock price increasing by 67% over the past year. This significant insider selling, particularly by CEO Strauss Zelnick, suggests a potential lack of confidence in future …

Takeda aims for dengue vaccine inclusion in India's shots program

Japanese drugmaker Takeda Pharmaceutical is seeking to integrate its newly approved dengue vaccine, Qdenga, into India's national immunization program. This move follows the vaccine's approval by India's Central Drugs Standard Control Organisation last month. The initiative aims to combat dengue fever, which infected 120,000 …

Take-Two Interactive Software's Fiscal Q1 Results to Reach Higher End of Guidance, Wedbush Says

Wedbush analysts expect Take-Two Interactive Software to report fiscal first-quarter results at the higher end of its guidance. This positive outlook is primarily driven by strong engagement with its popular "Grand Theft Auto V" and "Grand Theft Auto Online" titles. The firm anticipates the …

Militia Capital Management LLC Makes New Investment in Take-Two Interactive Software, Inc. $TTWO

Militia Capital Management LLC has initiated a new position in Take-Two Interactive Software (NASDAQ: TTWO), purchasing 6,030 shares valued at approximately $1.19 million. Institutional investors and hedge funds hold a significant 95.46% of the company's stock, while Wall Street analysts maintain a "Buy" rating …

Edgestream Partners L.P. Buys 10,078 Shares of Take-Two Interactive Software, Inc. $TTWO

Edgestream Partners L.P. significantly increased its stake in Take-Two Interactive Software (NASDAQ:TTWO) by 502.6% during the first quarter, purchasing an additional 10,078 shares to hold a total of 12,083 shares valued at $2.39 million. This move highlights strong institutional interest, with 95.46% of the …

(TTWO) Risk Channels and Responsive Allocation

This article provides an AI-generated analysis for Take-Two Interactive Software Inc. (NASDAQ: TTWO), highlighting a strong near-term sentiment with a neutral mid and long-term outlook. It identifies an exceptional short setup targeting a 10.6% downside with 0.3% risk and outlines three distinct trading strategies …

Take-Two Interactive Software, Inc. $TTWO Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Take-Two Interactive Software (TTWO) by 8.1% in the first quarter, selling 8,094 shares and retaining 91,301 shares valued at $18.0 million. Institutional investors own 95.46% of TTWO, while company insiders sold 569,936 shares worth $128.4 …

Quantinno Capital Management LP Grows Stock Holdings in Takeda Pharmaceutical Co. $TAK

Take-Two Interactive (TTWO) Stock Declines While Market Improves: Some Information for Investors

Take-Two Interactive (TTWO) stock recently declined by 1.82%, underperforming the S&P 500, Dow, and Nasdaq. The company is set to release its earnings report on August 7, 2026, with an anticipated EPS of $0.31, a 49.18% decrease year-over-year, and revenue of $1.35 billion, a …

Quantinno Capital Management LP Reduces Position in Take-Two Interactive Software, Inc. $TTWO

Quantinno Capital Management LP reduced its stake in Take-Two Interactive Software (NASDAQ:TTWO) by 6.7% in the first quarter of 2026, selling 8,877 shares and retaining 122,796 shares valued at $24.3 million. Despite this reduction, institutional ownership remains high at 95.46%, with major holders like …

Lido Advisors LLC Trims Position in Take-Two Interactive Software, Inc. $TTWO

Lido Advisors LLC reduced its stake in Take-Two Interactive Software, Inc. by 67.6% in the first quarter, now owning 2,149 shares worth $424,000. Other institutional investors also adjusted their holdings, with hedge funds and institutions collectively owning 95.46% of the company's stock. Insider selling …

Take-Two Interactive Software Inc. (TTWO) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Take-Two Interactive Software Inc. (TTWO) stock, showing its current price of $243.51 with a slight increase of $0.59 (0.24%). It notes that analyst ratings and earnings information are not currently available for the company. The page …

Take-Two Interactive Software Inc. stock underperforms Friday when compared to competitors

Take-Two Interactive Software Inc. (TTWO) stock fell by 1.82% on Friday, closing at $242.92, despite a positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains. The company's stock is currently 8.66% below its 52-week …

Takeda Ready to Resume Top-Line Growth With Refreshed Late-Stage Pipeline

Takeda Pharmaceutical, Japan's leading pharmaceutical company, is poised for top-line growth driven by a refreshed late-stage pipeline. The company has strategically diversified away from the stagnant Japanese market through significant acquisitions, notably the $57 billion purchase of Shire Plc in 2019, which expanded its …

Take-Two Interactive Software, Inc. $TTWO Shares Acquired by Sei Investments Co.

Sei Investments Co. increased its stake in Take-Two Interactive Software, Inc. (NASDAQ:TTWO) by 24.9% in the first quarter, now owning 79,679 shares valued at $15.74 million. Other institutional investors also adjusted their positions in TTWO, with significant purchases from firms like Davis R M …

California State Teachers Retirement System Has $59.26 Million Stock Position in Take-Two Interactive Software, Inc. $TTWO

The California State Teachers Retirement System (CalSTRS) reduced its stake in Take-Two Interactive Software (NASDAQ:TTWO) by 2.0% in the first quarter, selling 6,186 shares but still holding 300,041 shares valued at approximately $59.26 million. Institutional investors collectively own 95.46% of Take-Two's stock, while corporate …

Takeda (TSE:4502) Stock Struggles To Convert Revenue Growth Into Lasting Profit

Take-Two Interactive Software (TTWO) Projected to Announce Quarterly Earnings on Friday

Take-Two Interactive Software (TTWO) is expected to announce its Q1 2027 earnings after market close on Friday, August 7th, with analysts projecting earnings of $0.327 per share and revenues of $1.403 billion. The stock opened at $247.43, near its 12-month high, and holds a …

Takeda Pharmaceutical Maintained at "Neutral" by Major U.S. Securities Firm, Target Price Raised to ¥5,800

A major U.S. securities firm maintained its "Neutral" rating on Takeda Pharmaceutical but raised its target price to ¥5,800 following the company's April-June 2026 quarter results. While revenue increased due to a weaker yen, net profit declined due to higher SG&A and R&D expenses, …

Investors Heavily Search Take-Two Interactive Software, Inc. (TTWO): Here is What You Need to Know

Take-Two Interactive (TTWO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this publisher of …

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

Keros Therapeutics, Inc. LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of …

Takeda Pharmaceutical Q1 Earnings Call Highlights

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its mature portfolio. Revenue …

Earnings call transcript: Takeda Q1 2026 results show steady growth, stock slips premarket

Takeda Pharmaceutical reported Q1 2026 results indicating steady growth, with revenue reaching JPY 1.22 trillion, a 10.2% increase at actual exchange rates, though declining 0.5% at constant currency. Despite core EPS falling due to prior-year tax benefits, the company maintained its full-year guidance and …

Takeda Pharmaceutical (NYSE: TAK) Q1 2026 revenue ¥1.22T, EPS ¥71.65

Takeda Pharmaceutical Company Limited reported consolidated IFRS results for Q1 2026, with revenue reaching ¥1.22 trillion, a 10.2% year-on-year increase primarily due to Japanese yen depreciation. Despite increased revenue and operating profit, net profit attributable to owners declined by 8.9% to ¥113.2 billion, resulting …

Take-Two Interactive Software, Inc. $TTWO Shares Acquired by Amundi

Amundi increased its stake in Take-Two Interactive Software (NASDAQ:TTWO) by 38.1% in the first quarter, now owning 1.35% of the company's stock valued at $492.56 million. Other institutional investors have also adjusted their holdings, while insiders have sold a significant amount of shares. Analysts …

Takeda Pharmaceutical Company Limited bestätigt Gewinnprognose für das Geschäftsjahr 2026